Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Selecta and Takeda enter strategic licensing agreement for lysosomal storage disorders

Oct. 5, 2021

Modulating PPM1E is a therapeutic approach in type 2 diabetes

Oct. 5, 2021

Dare Bioscience awarded NICHD grant for DARE-LARC1 user-controlled contraceptive

Sep. 28, 2021

Discovery of novel EP3 receptor antagonists

Sep. 27, 2021

Servier discovers nuclear factor erythroid 2-related factor 2 activators

Sep. 27, 2021

Kallyope presents new free fatty acid FFA1 receptor agonists

Sep. 27, 2021

Lymph dysfunction identified as potential metabolic target

Sep. 23, 2021

Kyoto University develops sequence-selective mitochondrial DNA alkylators for mitochondrial diseases

Sep. 22, 2021

Clarus licenses rights to McGill technology to treat conditions associated with CoQ10 deficiencies

Sep. 17, 2021

Novel potent TGR5 agonist shows antidiabetic effects in TGR5(H88Y) mutant mice

Sep. 17, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...